GlassScriptPrepare for your visit
Joseph B Tawil
Cardiovascular Disease · New York, NY · NPI 1952555047
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$4,095.87
in general payments reported to CMS, 2019-2025 · $899 in 2025
The $899 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Who reported paying
General payments only, top 6 by amount.
- Boehringer Ingelheim Pharmaceuticals, INC. $787.75
- Novartis Pharmaceuticals Corporation $562.59
- Janssen Pharmaceuticals, INC $503.15
- Astrazeneca Pharmaceuticals LP $385.11
- Amgen INC. $301.81
- Pfizer INC. $284.97
Drugs and devices associated with these payments
Leqvio Kerendia Verquvo Jardiance Repatha Arcalyst Eliquis Camzyos Entresto Lokelma Farxiga Nurtec Odt
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Joseph Tawil listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/134366/joseph-b-tawil